

# Global RET Inhibitors Drug Market Opportunity & Clinical Trials Insight 2026

<https://marketpublishers.com/r/GE5C8394212AEN.html>

Date: March 2021

Pages: 150

Price: US\$ 2,400.00 (Single User License)

ID: GE5C8394212AEN

## Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

'Global RET Inhibitors Drug Market Opportunity & Clinical Trials Insight 2026' Report Highlights:

Global RET Inhibitors Market Opportunity: > USD 1.5 Billion

Global RET Inhibitors Market Absolute Growth : 3900% (2020-2026)

RET inhibitors clinical Trials Insight by Company, Country, Indication & Phase

RET Inhibitors In Clinical Trials: > 15 Drugs

Commercially Available RET Inhibitors: 2 (Retevmo and Gavreto)

First RET Inhibitor Approved In 2020: Retevmo

RET inhibitor therapy market is a novel, unique yet a challenging aspect followed by the oncology researchers for the treatment of different types of cancers. The total cancer mortality rate in the world had increased to such greater percentage that it was of utmost importance to come up with a therapeutic procedure that could effectively eradicate disease causing cells in the human body. Oncology researchers focused towards the development of a novel therapeutic for the patients landed with one of the most innovative and important breakthroughs as the therapy targets one of the most important proto-oncogene responsible for the initiation of cancerous cells inside the

body. It has been only few years since the total penetration of RET inhibitor therapy market in the global cancer therapeutics industry and in such short period of time, it has remained successful in emerging as the next strong pillar for the entire cancer therapeutics market, as it targets at the molecular level, which is apparently very less in the global cancer therapeutics market.

Major biopharmaceutical companies and biotech firms around the world have initiated several strategically important alliances which include partnerships, collaborations and many more, leading to gardening the entire therapy towards launching large number of drugs in the next few years. High inclination of oncology researchers towards the development and expansion of the therapy is also moving the entire market to receive high appreciation rate as it carries the ability to end all the challenges and complexities that were getting highly reported in the global cancer therapeutics market in the form of side-effects.

The entire research and growth frontiers associated with the therapy development and expansion rate are believed to increase at a higher percentage in the future years, observing the endless applications received from it. In addition, inclination of the therapy towards targeting different types of cancers such as non-small cell lung cancer, breast cancer, pancreatic cancer and many more is also inclining the entire therapy to get recognized as a viable, potential, terrifying market, compared with other cancer therapies available in the market for long period of time.

As per 'Global RET Inhibitors Drug Market Opportunity & Clinical Trials Insight 2026' findings, it is estimated that the complete emergence of the therapy at pre-clinical and clinical level has landed hundreds of novel treatment opportunities for the enrolled participants with respect to overall survival rate. Also, extensive amount of investments laid down for the therapy development and expansion worldwide by elite research centers and government bodies will also deliver and exhibit great amount of work that will soon incline the therapy towards passing early stage of development. With large number of investigational drugs in the clinical trial, the therapy is also attaining massive attraction from numerous clinical stage biotech companies focused towards multi-billion dollar investment and collaborations. To conclude, it can be stated that the future of the therapy will be adjoined with massive commercial success as there are several promising candidates in the pipeline. In addition, it is also believed to get transformed into a fundamental approach for the benefit of millions of patients.

## Contents

### **1. INTRODUCTION TO REARRANGED DURING TRANSFECTION (RET) INHIBITORS**

- 1.1 Overview
- 1.2 Evolution of RET Inhibitors

### **2. ROLE OF RET INHIBITORS IN CANCER**

### **3. RET INHIBITORS - MECHANISM OF ACTION**

### **4. RET INHIBITORS AS NON-SMALL CELL LUNG CANCER THERAPEUTICS**

- 4.1 Role of RET Inhibitors in NSCLC
- 4.2 Ongoing Research & Development
  - 4.2.1 TAS0953/HM06
  - 4.2.2 RXDX-105
  - 4.2.3 BOS172738
  - 4.2.4 TPX-0046

### **5. RET INHIBITORS AS THYROID CANCER THERAPEUTICS**

- 5.1 Impact of RET Inhibition on Thyroid Cancer
- 5.2 Current Advancements & Research

### **6. RET INHIBITORS IN COLORECTAL CANCER**

- 6.1 RET Gene Inhibition Influencing Colorectal Cancer
- 6.2 Ongoing Research & Development

### **7. RET INHIBITORS IN OTHER LEADING CANCERS**

- 7.1 RET Inhibitors in Breast Cancer
- 7.2 RET Inhibitors in Liver Cancer
- 7.3 RET Inhibitors in Melanoma
- 7.4 RET Inhibitors in Hematological Cancers
- 7.5 RET in Gastric Cancers

## **8. RET INHIBITORS IN COMBINATIONAL THERAPY**

## **9. GLOBAL RET INHIBITORS MARKET ANALYSIS**

9.1 Overview

9.2 Current Market Scenario

## **10. RET INHIBITORS MARKET OPPORTUNITIES BY REGION**

10.1 US

10.2 Europe

10.3 Japan

10.4 China

## **11. RETEVMO (SELPERCATINIB)**

11.1 Overview

11.2 Patents & Assignee

11.3 Dosage, Price & Sales Analysis

## **12. GAVRETO (PRALSETINIB)**

12.1 Overview & Patent Information

12.2 Dosage, Price & Sales Analysis

## **13. GLOBAL RET INHIBITORS CLINICAL TRIALS OVERVIEW**

13.1 By Phase

13.2 By Status

13.3 By Region

## **14. GLOBAL RET INHIBITORS CLINICAL TRIALS INSIGHT BY COUNTRY, COMPANY & INDICATION**

14.1 Research

14.2 Preclinical

14.3 Phase-I

14.4 Phase-I/II

14.5 Phase-II

## 14.6 Phase-III

## **15. APPROVED & MARKETED RET INHIBITORS CLINICAL INSIGHT**

15.1 Pralsetinib (Gavreto)

15.2 Selpercatinib (RETEVMO)

## **16. GLOBAL RET INHIBITORS MARKET TRENDS**

16.1 Voroni & Inno N Collaborated to Develop Novel RET Inhibitor Candidate

16.2 Researchers Identified First Mechanism of Resistance to Retevmo (Selpercatinib)

16.3 Helsinn Doses its Investigational RET Inhibitors in First Patient of Phase I/II Trial

16.4 TPX-0046 - Investigational RET Inhibitor Shows Prominent Results in Preclinical Studies

## **17. GLOBAL RET INHIBITORS MARKET DYNAMICS - DRIVERS & CHALLENGES**

17.1 Global RET Inhibitor Market Drivers

17.2 Challenges for Global RET Inhibitors Market

## **18. GLOBAL RET INHIBITORS MARKET - FUTURE OUTLOOK**

## **19. COMPETITIVE LANDSCAPE**

19.1 Boston Pharmaceuticals

19.2 Blueprint Therapeutics

19.3 Daiichi Sankyo

19.4 Eli Lilly

19.5 GSK

19.6 Helsinn

19.7 Ignyta

19.8 Inno N

19.9 LoxoOncology

19.10 Roche

19.11 Taiho

19.12 Turning Point Therapeutics

## List Of Figures

### LIST OF FIGURES

- Figure 1-1: Global – NSCLC Cancer Frequency by Mutation Types (%)
- Figure 1-2: Global – Thyroid Cancer Frequency by Mutation Types (%)
- Figure 1-3: Evolution of RET Inhibitors
- Figure 2-1: Frequency of RET Mutation in NSCLC & Papillary Thyroid Cancer (%)
- Figure 2-2: Frequency of RET Fusion by Medullary Thyroid Cancer Type (%)
- Figure 2-3: Frequency of RET Mutation by Cancer Type (%)
- Figure 2-4: Roles of RET Inhibitors in Cancer Management
- Figure 3-1: Pathways of RET Alteration in Cancer
- Figure 3-2: Outline of RET Signaling Pathway & Mechanism of RET Inhibitors
- Figure 3-3: Therapeutic Kinase Activity By Selectivity
- Figure 4-1: Global – Newly Diagnosed Cases & Deaths related to Lung Cancer (Million), 2020
- Figure 4-2: Global – Lung Cancer Share by Type (%), 2020
- Figure 4-3: Fusion Partners Required for RET Mutation in NSCLC
- Figure 4-4: Activity of RET Inhibitors in RET-Mutated NSCLC
- Figure 4-5: Investigational RET Inhibitors for NSCLC
- Figure 4-6: TAS0953/HM06 Phase I/II Trial – Study Initiation & Expected Completion Year
- Figure 4-7: BOS172738 Phase I Trial – Study Initiation & Expected Completion Year
- Figure 4-8: TPX-0046 Phase I/II Trial – Study Initiation & Expected Completion Year
- Figure 5-1: Global – Number of Newly Diagnosed Liver Cancer Cases, 2020, 2025 & 2030
- Figure 5-2: Global – Number of Newly Diagnosed Liver Cancer Cases (Million), 2020, 2025 & 2030
- Figure 5-3: Roles of RET Inhibitors in Thyroid Cancer Management
- Figure 5-4: Retevmo Phase III Trial – Study Initiation & Expected Completion Year
- Figure 5-5: Retevmo Phase II Trial – Study Initiation & Expected Completion Year
- Figure 5-6: Gavreto Phase III Trial – Study Initiation & Expected Completion Year
- Figure 6-1: Global – Estimated Newly Diagnosed Colon Cancer Cases (Million), 2020, 2025 & 2030
- Figure 6-2: Global – Estimated Colon Cancer Deaths, 2020, 2025 & 2030
- Figure 6-3: Global – Estimated Newly Diagnosed Rectum Cancer Cases, 2020, 2025 & 2030
- Figure 6-4: Global – Estimated Rectum Cancer Deaths, 2020, 2025 & 2030
- Figure 6-5: Mechanism of RET Inhibitors in Colorectal Cancer

Figure 6-6: Retevmo Phase I/II Trial – Study Initiation & Expected Completion Year

Figure 6-7: Gavreto Phase I/II Trial – Study Initiation & Expected Completion Year

Figure 7-1: Global – Number of Newly Diagnosed Breast Cancer Cases (Million), 2020, 2025 & 2030

Figure 7-2: Global – Number of Newly Diagnosed Breast Cancer Cases (Million), 2020, 2025 & 2030

Figure 7-3: Common Types of RET Alterations in Breast Cancer

Figure 7-4: Global – Number of Newly Diagnosed Liver Cancer Cases (Million), 2020, 2025 & 2030

Figure 7-5: Global – Number of Newly Diagnosed Liver Cancer Cases (Million), 2020, 2025 & 2030

Figure 7-6: Global – RET Mutation Frequency by Liver Cancer Type (%), 2020

Figure 7-7: Roles of RET Inhibitors in Liver Cancer Management

Figure 7-8: Global – Number of Newly Diagnosed Melanoma Cases, 2020, 2025 & 2030

Figure 7-9: Global – Number of Newly Diagnosed Melanoma Cases, 2020, 2025 & 2030

Figure 7-10: US – Estimated Newly Diagnosed Blood Cancer Cases by Type, 2020

Figure 7-11: US – Estimated Blood Cancer Deaths by Type, 2020

Figure 7-12: Global – RET Mutation Frequency by Hematological Cancer Type (%), 2020

Figure 7-13: Mechanism of RET Inhibitors in Hematological Cancers

Figure 7-14: Global – Number of Newly Diagnosed Gastric Cancer Cases (Million), 2020, 2025 & 2030

Figure 7-15: Global – Number of Newly Diagnosed Gastric Cancer Cases, 2020, 2025 & 2030

Figure 7-16: Global – RET Mutation Frequency by Gastric Cancer Type (%), 2020

Figure 8-1: Drug Classes Used in Combination with RET Inhibitors

Figure 9-1: Global – Number of Newly Diagnosed Cancer Cases (Million), 2020, 2025 & 2030

Figure 9-2: Global – Number of Cancer Deaths (Million), 2020, 2025 & 2030

Figure 9-3: Global – NSCLC Drugs Market Size (US\$ Billion), 2020 - 2026

Figure 9-4: Global – Thyroid Cancer Drugs Market Size (US\$ Billion), 2020 - 2026

Figure 9-5: Global – Cancer Drug Market Size (US\$ Billion), 2020 - 2025

Figure 9-6: Global – RET Inhibitors Market Opportunity (US\$ Million), 2020 - 2026

Figure 9-7: Global – RET Inhibitors Market by Product (US\$ Million), 2020

Figure 9-8: Global – RET Inhibitors Market by Product (%), 2020

Figure 10-1: US – Number of Newly Diagnosed Cancer Cases (Million), 2020, 2025 & 2030

Figure 10-2: US – Number of Cancer Deaths, 2020, 2025 & 2030

Figure 10-3: US – RET Inhibitors Market Opportunity (US\$ Million), 2020 - 2026

Figure 10-4: US – Tyrosine Kinase Inhibitors Market Opportunity (US\$ Million), 2020 - 2026

Figure 10-5: US – RET Inhibitors Market Opportunity by 1% of Tyrosine Kinase Inhibitors Market (US\$ Million), 2021 - 2026

Figure 10-6: US – RET Inhibitors Market Opportunity by 2% of Tyrosine Kinase Inhibitors Market (US\$ Million), 2021 - 2026

Figure 10-7: US – RET Inhibitors Market Opportunity by 3% of Tyrosine Kinase Inhibitors Market (US\$ Million), 2021 - 2026

Figure 10-8: US – RET Inhibitors Market Opportunity by 4% of Tyrosine Kinase Inhibitors Market (US\$ Million), 2021 - 2026

Figure 10-9: US – RET Inhibitors Market Opportunity by 5% of Tyrosine Kinase Inhibitors Market (US\$ Million), 2021 - 2026

Figure 10-10: Europe – Number of Newly Diagnosed Cancer Cases (Million), 2020, 2025 & 2030

Figure 10-11: Europe – Number of Cancer Deaths, 2020, 2025 & 2030

Figure 10-12: Europe – RET Inhibitors Market Opportunity (US\$ Million), 2021 - 2026

Figure 10-13: Japan – Number of Newly Diagnosed Cancer Cases, 2020, 2025 & 2030

Figure 10-14: Japan – Number of Cancer Deaths, 2020, 2025 & 2030

Figure 10-15: Japan – RET Inhibitors Market Opportunity (US\$ Million), 2021 - 2026

Figure 10-16: China – Number of Newly Diagnosed Cancer Cases (Million), 2020, 2025 & 2030

Figure 10-17: China – Number of Cancer Deaths (Million), 2020, 2025 & 2030

Figure 10-18: China – Cancer Drug Market Opportunity (US\$ Billion), 2020 - 2026

Figure 10-19: China – Tyrosine Kinase Inhibitors Market Opportunity (US\$ Billion), 2020 - 2026

Figure 10-20: China – RET Inhibitors Market Opportunity by 1% of Tyrosine Kinase Inhibitors Market (US\$ Million), 2021 - 2026

Figure 10-21: China – RET Inhibitors Market Opportunity by 2% of Tyrosine Kinase Inhibitors Market (US\$ Million), 2021 - 2026

Figure 10-22: China – RET Inhibitors Market Opportunity by 3% of Tyrosine Kinase Inhibitors Market (US\$ Million), 2021 - 2026

Figure 10-23: China – RET Inhibitors Market Opportunity by 4% of Tyrosine Kinase Inhibitors Market (US\$ Million), 2021 - 2026

Figure 10-24: China – RET Inhibitors Market Opportunity by 5% of Tyrosine Kinase Inhibitors Market (US\$ Million), 2021 - 2026

Figure 11-1: Retevmo – FDA Approval & Orphan Designation Year

Figure 11-2: Retevmo – Patent Issue & Expiration Year

Figure 11-3: Retevmo – Price for 60 Capsules & Price Per Unit Capsules of 40mg (US\$), March'2021



Figure 11-4: Retevmo – Price for 60 Capsules & Price Per Unit Capsules of 80mg (US\$), March'2021

Figure 11-5: Retevmo – Price for 120 Capsules & Price Per Unit Capsules of 80mg (US\$), March'2021

Figure 11-6: Retevmo – Recommended Initial & Reduced Dose for Patients with Weight less than 50Kg (mg/day)

Figure 11-7: Retevmo – Recommended Initial & Reduced Dose for Patients with Weight More Than 50Kg (mg/day)

Figure 11-8: Retevmo – Quarterly Sales Value (US\$ Million), Q2-Q4, 2020

Figure 12-1: Gavreto – FDA Approval & Orphan Designation Year

Figure 12-2: Gavreto – Patent Issue & Expiration Year

Figure 12-3: Gavreto – Price for 60 Capsules & Price Per Unit Capsules (US\$), March'2021

Figure 12-4: Gavreto – Price for 120 Capsules & Price Per Unit Capsules (US\$), March'2021

Figure 12-5: Gavreto – Recommended Initial & Reduced Dose for Patients (mg/day)

Figure 13-1: Global – Number of RET Inhibitors Related Clinical Trials by Phase, March'2021

Figure 13-2: Global – Number of RET Inhibitors Related Clinical Trials by Phase (%), March'2021

Figure 13-3: Global – Number of RET Inhibitors Related Clinical Trials by Status, March'2021

Figure 13-4: Global – Number of RET Inhibitors Related Clinical Trials by Status (%), March'2021

Figure 13-5: Global – Number of RET Inhibitors Related Clinical Trials by Region, March'2021

Figure 13-6: Global – Number of RET Inhibitors Related Clinical Trials by Region (%), March'2021

Figure 17-1: Global RET Inhibitors Market Drivers

Figure 17-2: Challenges for Global RET Inhibitors Market

Figure 17-3: US – Daily Treatment Cost Comparison of NSCLC by Kinase inhibitors Drugs (US\$), March'2021

Figure 17-4: US – Daily Treatment Cost Comparison of Thyroid Cancer by Kinase Inhibitors Drugs (US\$), March'2021

## I would like to order

Product name: Global RET Inhibitors Drug Market Opportunity & Clinical Trials Insight 2026

Product link: <https://marketpublishers.com/r/GE5C8394212AEN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE5C8394212AEN.html>